Pazopanib hydrochloride

Pazopanib hydrochloride

File:Pazopanib structure.svg
Clinical data
Trade names	Votrient
AHFS/Drugs.com	Monograph
MedlinePlus	a610013
[[Regulation of therapeutic goods |Template:Engvar data]]	EU EMA: by INN US FDA: Pazopanib
Pregnancy category	US: D (Evidence of risk)
Routes of administration	Oral
ATC code	L01XE11 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	>99%
Metabolism	Hepatic (CYP3A4, 1A2 and 2C8-mediated)
Elimination half-life	31 hours (mean)
Excretion	Mostly fecal
Identifiers
IUPAC name 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzolsulfonamide
CAS Number	444731-52-6 N
PubChem CID	11525740
ChemSpider	9700526 Y
UNII	7RN5DR86CK
ChEMBL	ChEMBL477772 N
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C21H23N7O2S
Molar mass	437.517 g/mol
3D model (JSmol)	Interactive image
SMILES Cl.O=S(=O)(N)c1c(ccc(c1)Nc2nccc(n2)N(c4ccc3c(nn(c3C)C)c4)C)C
InChI InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H Y Key:MQHIQUBXFFAOMK-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

WikiDoc Resources for Pazopanib hydrochloride
Articles
Most recent articles on Pazopanib hydrochloride Most cited articles on Pazopanib hydrochloride Review articles on Pazopanib hydrochloride Articles on Pazopanib hydrochloride in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Pazopanib hydrochloride Images of Pazopanib hydrochloride Photos of Pazopanib hydrochloride Podcasts & MP3s on Pazopanib hydrochloride Videos on Pazopanib hydrochloride
Evidence Based Medicine
Cochrane Collaboration on Pazopanib hydrochloride Bandolier on Pazopanib hydrochloride TRIP on Pazopanib hydrochloride
Clinical Trials
Ongoing Trials on Pazopanib hydrochloride at Clinical Trials.gov Trial results on Pazopanib hydrochloride Clinical Trials on Pazopanib hydrochloride at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Pazopanib hydrochloride NICE Guidance on Pazopanib hydrochloride NHS PRODIGY Guidance FDA on Pazopanib hydrochloride CDC on Pazopanib hydrochloride
Books
Books on Pazopanib hydrochloride
News
Pazopanib hydrochloride in the news Be alerted to news on Pazopanib hydrochloride News trends on Pazopanib hydrochloride
Commentary
Blogs on Pazopanib hydrochloride
Definitions
Definitions of Pazopanib hydrochloride
Patient Resources / Community
Patient resources on Pazopanib hydrochloride Discussion groups on Pazopanib hydrochloride Patient Handouts on Pazopanib hydrochloride Directions to Hospitals Treating Pazopanib hydrochloride Risk calculators and risk factors for Pazopanib hydrochloride
Healthcare Provider Resources
Symptoms of Pazopanib hydrochloride Causes & Risk Factors for Pazopanib hydrochloride Diagnostic studies for Pazopanib hydrochloride Treatment of Pazopanib hydrochloride
Continuing Medical Education (CME)
CME Programs on Pazopanib hydrochloride
International
Pazopanib hydrochloride en Espanol Pazopanib hydrochloride en Francais
Business
Pazopanib hydrochloride in the Marketplace Patents on Pazopanib hydrochloride
Experimental / Informatics
List of terms related to Pazopanib hydrochloride

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by the U.S. Food and Drug Administration. Pazopanib may also be active in ovarian cancer Pazopanib also appears effective in the treatment of non-small cell lung carcinoma.